menu
    • menu
    [{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sentynl Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sentynl Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Agreement","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.13,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Sentynl Therapeutics

    Menu

    Sentynl Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 for Menkes Disease

                            Details : CUTX-101 is a subcutaneous injectable formulation of copper histidinate, which is being evaluated for the treatment of menkes disease.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sentynl Receives MHRA Authorization for NULIBRY® in MoCD Type A

                            Details : Nulibry (fosdenopterin) is the first therapy for patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare genetic disorder that often progresses rapidly in infants.

                            Product Name : Nulibry

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sentynl Acquires Zokinvy® for Hutchinson-Gilford Progeria Syndrome

                            Details : Sentynl will commercialize Zokinvy (lonafarnib) globally, the first FDA-approved treatment targeting progeria symptoms.

                            Product Name : Zokinvy

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 05, 2024

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histi...

                            Details : Under the agreement, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 (copper histidinate) product candidate for the treatment of Menkes disease, to Sentynl.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopt...

                            Details : NULIBRY (fosdenopterin) is first and only approved therapy in U.S. and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about fou...

                            Product Name : Nulibry

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 08, 2022

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopter...

                            Details : Nulibry (fosdenopterin) is a first-in-class cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A.

                            Product Name : Nulibry

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 20, 2022

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRYâ„...

                            Details : Under the Agreement, Sentynl will acquire global rights to NULIBRY and will be responsible for the ongoing development and commercialization of NULIBRY in the United States and developing, manufacturing and commercializing Fosdenopterin globally.

                            Product Name : Nulibry

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 03, 2022

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY (fosdenopterin) for the Tr...

                            Details : CHMP recommendation for approval of NULIBRY (fosdenopterin) in European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural ...

                            Product Name : Nulibry

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 25, 2022

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics and Sentynl Therapeutics Sign Development and Asset Purchase Agreement

                            Details : Sentynl has signed an agreement with Cyprium to contribute research funding for CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease, and to purchase Cyprium's proprietary rights to CUTX-101.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : $20.0 million

                            February 24, 2021

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Copper Histidinate Treatment for Menkes Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 30, 2019

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth